Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone49-62-2165-3070
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$28.03 million
Profitability
Miscellaneous
Employees8,406
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Affimed (NASDAQ:AFMD) Frequently Asked Questions
What is Affimed's stock symbol?
Affimed trades on the NASDAQ under the ticker symbol "AFMD."
How were Affimed's earnings last quarter?
Affimed NV (NASDAQ:AFMD) announced its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.16). The biopharmaceutical company earned $4.50 million during the quarter, compared to the consensus estimate of $6.46 million. Affimed had a negative return on equity of 30.94% and a negative net margin of 30.87%. View Affimed's Earnings History.
When is Affimed's next earnings date?
What price target have analysts set for AFMD?
6 analysts have issued 12 month target prices for Affimed's shares. Their forecasts range from $4.00 to $10.00. On average, they expect Affimed's stock price to reach $6.0283 in the next twelve months. This suggests a possible upside of 113.0% from the stock's current price. View Analyst Price Targets for Affimed.
What is the consensus analysts' recommendation for Affimed?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Affimed.
Has Affimed been receiving favorable news coverage?
Press coverage about AFMD stock has been trending negative this week, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Affimed earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Affimed.
Who are some of Affimed's key competitors?
Some companies that are related to Affimed include Achillion Pharmaceuticals (ACHN), Stemline Therapeutics (STML), Vectura Group (VEGPF), ZEALAND PHARMA/S (ZEAL), Myovant Sciences (MYOV), Morphic (MORF), TG Therapeutics (TGTX), NextCure (NXTC), Akebia Therapeutics (AKBA), Karyopharm Therapeutics (KPTI), Rocket Pharmaceuticals (RCKT), Endo International (ENDP), DiaMedica Therapeutics (DMCAF), Catalyst Pharmaceuticals (CPRX) and INDIVIOR PLC/S (INVVY).
What other stocks do shareholders of Affimed own?
Who are Affimed's key executives?
Affimed's management team includes the folowing people:
- Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)
- Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)
- Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)
- Prof. Melvyn Little, Founder & Consultant
- Dr. Martin Treder, Chief Scientific Officer (Age 49)
Who are Affimed's major shareholders?
Affimed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.69%), Acadian Asset Management LLC (3.49%), Stonepine Capital Management LLC (1.15%), Canada Pension Plan Investment Board (0.32%), GSA Capital Partners LLP (0.27%) and Jane Street Group LLC (0.26%).
Which institutional investors are selling Affimed stock?
AFMD stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN and Weiss Asset Management LP.
Which institutional investors are buying Affimed stock?
AFMD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Acadian Asset Management LLC, Stonepine Capital Management LLC, Canada Pension Plan Investment Board, GSA Capital Partners LLP, Jane Street Group LLC, Charles Schwab Investment Management Inc. and Bank of New York Mellon Corp.
How do I buy shares of Affimed?
Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affimed's stock price today?
One share of AFMD stock can currently be purchased for approximately $2.83.
How big of a company is Affimed?
Affimed has a market capitalization of $176.56 million and generates $28.03 million in revenue each year. The biopharmaceutical company earns $-23,000,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Affimed employs 8,406 workers across the globe.View Additional Information About Affimed.
What is Affimed's official website?
How can I contact Affimed?
Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2165-3070 or via email at [email protected]
MarketBeat Community Rating for Affimed (NASDAQ AFMD)
MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
